|

Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease

RECRUITINGN/ASponsored by Fujian Medical University Union Hospital
Actively Recruiting
PhaseN/A
SponsorFujian Medical University Union Hospital
Started2025-04-16
Est. completion2029-04-30
Eligibility
Age50 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07324161

Summary

This study is grounded in the regulatory mechanisms of the glymphatic system and applies repetitive transcranial magnetic stimulation (rTMS) to the treatment of Alzheimer's disease (AD). The clinical efficacy and safety of rTMS will be systematically evaluated. Furthermore, transcranial magnetic stimulation-evoked potentials (TMS-EEG) and functional near-infrared spectroscopy (fNIRS) will be employed to investigate, from the perspectives of synaptic plasticity and neurovascular coupling, the mechanisms by which rTMS influences glymphatic function. Collectively, this work aims to provide new insights into both the therapeutic effectiveness and the underlying mechanisms of rTMS in AD.

Eligibility

Age: 50 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Meets the 2018 NIA-AA diagnostic criteria for Alzheimer's disease (AD)
* Meets DSM-5 diagnostic criteria
* Mild to moderate disease severity (CDR Global Score 1 to 2)
* Evidence of AD pathology: positive amyloid PET OR positive cerebrospinal fluid (CSF) AD biomarkers OR positive plasma AD biomarkers

Exclusion Criteria:

* Contraindications to rTMS treatment
* Severe complications or immune diseases
* Unable to cooperate with study procedures
* History of epilepsy

Conditions1

Alzheimer's Disease

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.